These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8645893)

  • 1. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Snydman DR
    Clin Transplant; 1995 Dec; 9(6):490-1. PubMed ID: 8645893
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Glowacki LS; Smaill FM
    Clin Transplant; 1994 Feb; 8(1):10-8. PubMed ID: 8136560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?
    Singh N
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):643-6. PubMed ID: 12373496
    [No Abstract]   [Full Text] [Related]  

  • 4. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 6. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
    Meylan PR; Pascual M
    Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with intravenous immune globulin.
    Snydman DR
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):20-5. PubMed ID: 1647560
    [No Abstract]   [Full Text] [Related]  

  • 8. CMV-enriched immune globulin produces consistent reliable results in renal transplant patients.
    Finn WF
    Transplantation; 1993 Aug; 56(2):491. PubMed ID: 7689267
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of intravenous immune globulin in organ transplantation.
    Platt D; Maderazo E; Chime-Udeh E
    Conn Med; 1991 Aug; 55(8):468-70. PubMed ID: 1657517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus infection in organ transplant recipients.
    Hibberd PL; Snydman DR
    Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease.
    Glowacki LS; Smaill FM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1408-10. PubMed ID: 8382863
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin.
    Valantine HA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):49-57. PubMed ID: 7482821
    [No Abstract]   [Full Text] [Related]  

  • 13. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients.
    King SM
    Antiviral Res; 1999 Jan; 40(3):115-37. PubMed ID: 10027647
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of intravenous immunoglobulin preparations in chronic lung diseases].
    Jankowska R
    Postepy Hig Med Dosw; 2002; 56 Suppl():49-52. PubMed ID: 12661414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones C; Craig JC
    Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
    Puius YA; Snydman DR
    Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cytomegalovirus immune globulin.
    Snydman DR
    Clin Pharm; 1992 Aug; 11(8):674-5. PubMed ID: 1324822
    [No Abstract]   [Full Text] [Related]  

  • 19. Indirect effects of CMV in the solid organ transplant patient.
    Paya CV
    Transpl Infect Dis; 1999; 1 Suppl 1():8-12. PubMed ID: 11565588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.